$RXRX Cashflow Statement | Understand Stock

$RXRX

$4.05 +$0.25 (6.58%) Close

$RXRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Asset impairment
Lease expense
Loss on debt extinguishment
Loss on disposal of a business
Acquired IPR&D
Other, net
Changes in operating assets and liabilities:
Accounts receivable
Other receivables and assets
Prepaid data assets
Unearned revenue
Accounts payable
Accrued development expense
Accrued expenses and other current liabilities
Lease liabilities

Net cash used in operating activities
Cash flows from investing activities
Net cash acquired in the acquisition of a business
Purchases of property and equipment
Purchases of intangible assets
Proceeds from note receivable
Decrease in cash related to disposal of a business
Purchases of investments
Sales and maturities of investments
Net cash provided by (used in) investing activities

Cash flows from financing activities
Proceeds from issuance of common shares, net of issuance costs
Proceeds from initial public offering of common stock, net of issuance costs
Proceeds from sale of preferred stock, net of issuance costs
Proceeds from equity incentive plans
Proceeds from long-term debt
Proceeds from convertible notes
Payments of debt issuance costs
Repayment of long-term debt and finance lease liabilities
Purchase of an intangible asset
Net cash provided by financing activities

Effect of exchange rate changes on cash, cash equivalents and restricted cash
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosure of non-cash investing and financing information
Issuance of shares for the acquisitions of businesses and agreement
Tempus agreement
Total issuance of shares for the acquisitions of businesses and agreement
Right-of-use asset additions and modifications
Accrued property and equipment
Conversion of preferred stock to common stock
Conversion of convertible notes to equity
Deferred issuance costs recorded in equity

Cash paid for operating leases
Cash paid for interest
Purchase of an intangible asset

Comments